Research & Literature

Urticaria and Prodromal Symptoms Including Erythema Marginatum in Danish Patients with Hereditary Angioedema.

Rasmussen ER, de Freitas PV, Bygum A

Acta dermato-venereologica 2016; (96(3)):373-6 doi:10.2340/00015555-2233.

Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.

Lumry WR, Farkas H, Moldovan D, et al.

International archives of allergy and immunology 2015; (168(1)):44-55 doi:10.1159/000441060.

Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor.

Farkas H, Kőhalmi KV, Veszeli N, et al.

Allergy and asthma proceedings 2016; (37(2)):164-70 doi:10.2500/aap.2016.37.3933.

HAE Pathophysiology and Underlying Mechanisms.

Zuraw BL, Christiansen SC

Clinical reviews in allergy & immunology 2016; (51(2)):216-29 doi:10.1007/s12016-016-8561-8.

Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting.

Zanichelli A, Longhurst HJ, Maurer M, et al.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2016; (117(4)):394-398 doi:10.1016/j.anai.2016.08.014.

Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.

Joseph K, Tholanikunnel BG, Kaplan AP

The Journal of allergy and clinical immunology 2017; (140(1)):170-176 doi:10.1016/j.jaci.2016.09.032.

Health-related quality of life among children with hereditary angioedema.

Engel-Yeger B, Farkas H, Kivity S, et al.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017; (28(4)):370-376 doi:10.1111/pai.12712.

A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.

Kőhalmi KV, Veszeli N, Cervenak L, et al.

Immunology letters 2017; (189()):90-93 doi:10.1016/j.imlet.2017.05.015.

Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema.

Bafunno V, Firinu D, D'Apolito M, et al.

The Journal of allergy and clinical immunology 2018; (141(3)):1009-1017 doi:10.1016/j.jaci.2017.05.020.

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.

Aberer W, Maurer M, Bouillet L, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2017; (13()):31 doi:10.1186/s13223-017-0203-z.

The relationship between anxiety and quality of life in children with hereditary angioedema.

Kessel A, Farkas H, Kivity S, et al.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017; (28(7)):692-698 doi:10.1111/pai.12758.

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies.

Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M

Orphanet journal of rare diseases 2018; (13(1)):73 doi:10.1186/s13023-018-0815-5.

Recurrent Acute Abdomen as the Main Manifestation of Hereditary Angioedema.

Iwanami K, Okano T, Ohara O, Morio T

Internal medicine (Tokyo, Japan) 2019; (58(2)):213-216 doi:10.2169/internalmedicine.1559-18.

The physician and hereditary angioedema friend or foe: 62-year diagnostic delay and iatrogenic procedures.

Valerieva A, Cicardi M, Baraniuk J, Staevska M

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2018; (14()):75 doi:10.1186/s13223-018-0275-4.

Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.

Murphy E, Donahue C, Omert L, et al.

Nursing open 2019; (6(1)):126-135 doi:10.1002/nop2.194.

Delayed diagnosis of hereditary angioedema with C1-inhibitor deficiency in iranian children and adolescents.

Ayazi M, Fazlollahi MR, Mohammadzadeh I, et al.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2019; (30(3)):395-398 doi:10.1111/pai.13028.

Hereditary angioedema in Austria: prevalence and regional peculiarities.

Schöffl C, Wiednig M, Koch L, et al.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2019; (17(4)):416-423 doi:10.1111/ddg.13815.

A review of kallikrein inhibitor lanadelumab in hereditary angioedema.

Hwang G, Johri A, Ng S, Craig T

Immunotherapy 2019; (11(11)):937-944 doi:10.2217/imt-2018-0197.

Hereditary angioedema: an update on causes, manifestations and treatment.

Longhurst HJ, Bork K

British journal of hospital medicine (London, England : 2005) 2019; (80(7)):391-398 doi:10.12968/hmed.2019.80.7.391.

The functional promoter F12-46C/T variant predicts the asymptomatic phenotype of C1-INH-HAE.

Rijavec M, Košnik M, Andrejević S, et al.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2019; (49(11)):1520-1522 doi:10.1111/cea.13470.

HEREDITARY ANGIOEDEMA DUE TO C1-INHIBITOR DEFICIENCY IN PEDIATRIC PATIENTS IN CROATIA - FIRST NATIONAL STUDY, DIAGNOSTIC AND PROPHYLACTIC CHALLENGES.

Karadža-Lapić L, Barešić M, Vrsalović R, et al.

Acta clinica Croatica 2019; (58(1)):139-146 doi:10.20471/acc.2019.58.01.18.

Hereditary angio-oedema as a rare cause of small-bowel obstruction.

Jamil B, Naeem MS, Anachebe T, Majeed MH

BMJ case reports 2019; (12(10)) doi:10.1136/bcr-2019-231186.

Bradykinin receptors: Agonists, antagonists, expression, signaling, and adaptation to sustained stimulation.

Marceau F, Bachelard H, Bouthillier J, et al.

International immunopharmacology 2020; (82()):106305 doi:10.1016/j.intimp.2020.106305.

The central role of endothelium in hereditary angioedema due to C1 inhibitor deficiency.

Wu MA, Bova M, Berra S, et al.

International immunopharmacology 2020; (82()):106304 doi:10.1016/j.intimp.2020.106304.

Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema.

Bernstein JA, Schwartz L, Yang W, et al.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2020; (125(3)):334-340.e1 doi:10.1016/j.anai.2020.05.015.

The Importance of Complement Testing in Acquired Angioedema Related to Angiotensin-Converting Enzyme Inhibitors.

Balla Z, Zsilinszky Z, Pólai Z, et al.

The journal of allergy and clinical immunology. In practice 2021; (9(2)):947-955 doi:10.1016/j.jaip.2020.08.052.

Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).

Wedner HJ

Allergy and asthma proceedings 2020; (41(Suppl 1)):S14-S17 doi:10.2500/aap.2020.41.200081.

Clinical presentation of hereditary angioedema.

Azmy V, Brooks JP, Hsu FI

Allergy and asthma proceedings 2020; (41(Suppl 1)):S18-S21 doi:10.2500/aap.2020.41.200065.

Successful perioperative management of three patients with hereditary angioedema without C1 esterase inhibitor therapy: A developing country perspective.

Jindal AK, Singh A, Anjani G, et al.

Immunobiology 2020; (225(6)):152022 doi:10.1016/j.imbio.2020.152022.

The Challenges in the Follow-Up and Treatment of Brazilian Children with Hereditary Angioedema.

Araújo-Simões J, Boanova AGP, Constantino-Silva RN, et al.

International archives of allergy and immunology 2021; (182(7)):585-591 doi:10.1159/000512944.

Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema.

Maurer M, Magerl M

Clinical reviews in allergy & immunology 2021; (61(1)):40-49 doi:10.1007/s12016-021-08841-w.

Acute Presentation of Undiagnosed Hereditary Angioedema of the Larynx: Averting Death.

Rajan N, Sharma V, Patro SK, Goyal A

Turkish archives of otorhinolaryngology 2020; (58(4)):279-281 doi:10.5152/tao.2020.5994.

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.

Lumry WR, Zuraw B, Cicardi M, et al.

Orphanet journal of rare diseases 2021; (16(1)):86 doi:10.1186/s13023-020-01658-4.

Periodic Severe Angioedema without Exogenous Hormone Exposure.

Nabavi M, Bahrami S, Arshi S, et al.

Iranian journal of allergy, asthma, and immunology 2021; (20(1)):120-124 doi:10.18502/ijaai.v20i1.5419.

Real-world off-label use of icatibant for acute management of non-hereditary angioedema.

Le TA, Smith W, Hissaria P

Internal medicine journal 2021; (51(3)):419-423 doi:10.1111/imj.15241.

Unnecessary Abdominal Surgeries in Attacks of Hereditary Angioedema with Normal C1 Inhibitor.

Gutierrez M, Veronez CL, Rodrigues Valle SO, et al.

Clinical reviews in allergy & immunology 2021; (61(1)):60-65 doi:10.1007/s12016-021-08852-7.

Subcutaneous C1-Inhibitor Concentrate for prophylaxis during pregnancy and lactation in a patient with C1-INH-HAE.

Andarawewa S, Aygören-Pürsün E

Clinical case reports 2021; (9(3)):1273-1275 doi:10.1002/ccr3.3743.

Short-term prophylaxis for children and adolescents with hereditary angioedema.

Ajewole O, Lanlokun M, Dimanche S, Craig T

Allergy and asthma proceedings 2021; (42(3)):205-213 doi:10.2500/aap.2021.42.210006.

Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.

Banerji A, Bernstein JA, Johnston DT, et al.

Allergy 2022; (77(3)):979-990 doi:10.1111/all.15011.

When the Red Tide Rolls In: A Red Tide Associated Angioedema Case Report.

Rabinowitz S, Solano JJ

Clinical practice and cases in emergency medicine 2021; (5(2)):222-225 doi:10.5811/cpcem.2021.3.51920.

Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists.

Manning ME

Dermatology and therapy 2021; (11(5)):1829-1838 doi:10.1007/s13555-021-00593-x.

HAE patient self-sampling for biomarker establishment.

Förster TM, Magerl M, Maurer M, et al.

Orphanet journal of rare diseases 2021; (16(1)):399 doi:10.1186/s13023-021-02021-x.

Medical algorithm: Management of C1 inhibitor hereditary angioedema.

Caballero T, Cabañas R, Pedrosa M

Allergy 2022; (77(3)):1060-1063 doi:10.1111/all.15115.

The role of C1 inhibitor and complement as acute phase reactants: are we missing the diagnosis of hereditary angioedema?

Stepaniuk P, Bosonea AM, Pourshahnazari P, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2021; (17(1)):103 doi:10.1186/s13223-021-00607-5.

The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.

Maurer M, Magerl M, Betschel S, et al.

The World Allergy Organization journal 2022; (15(3)):100627 doi:10.1016/j.waojou.2022.100627.

Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency.

Zanichelli A, Montinaro V, Triggiani M, et al.

Expert opinion on emerging drugs 2022; (27(2)):103-110 doi:10.1080/14728214.2022.2105834.

SERPING1 Variants and C1-INH Biological Function: A Close Relationship With C1-INH-HAE.

Drouet C, López-Lera A, Ghannam A, et al.

Frontiers in allergy 2022; (3()):835503 doi:10.3389/falgy.2022.835503.

Abdominal and pelvic imaging in the diagnosis of acute abdominal attacks in patients with hereditary angioedema due to C1-inhibitor deficiency.

Obtułowicz P, Stobiecki M, Dyga W, et al.

Postepy dermatologii i alergologii 2022; (39(4)):749-756 doi:10.5114/ada.2021.108438.

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.

Guo Y, Zhang H, Lai H, et al.

Orphanet journal of rare diseases 2022; (17(1)):399 doi:10.1186/s13023-022-02536-x.

A review of berotralstat for the treatment of hereditary angioedema.

Farkas H, Balla Z

Expert review of clinical immunology 2023; (19(2)):145-153 doi:10.1080/1744666X.2023.2150611.

Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology.

Sinnathamby ES, Issa PP, Roberts L, et al.

Advances in therapy 2023; (40(3)):814-827 doi:10.1007/s12325-022-02401-0.

Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency.

Miyata T, Horiuchi T

Allergology international : official journal of the Japanese Society of Allergology 2023; (72(3)):375-384 doi:10.1016/j.alit.2023.04.004.

A safety review of prophylaxis drugs for adolescent patients with hereditary angioedema.

Farkas H, Balla Z

Expert opinion on drug safety 2023; (22(7)):549-561 doi:10.1080/14740338.2023.2226861.

Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent.

Jindal AK, Sil A, Aggarwal R, et al.

Asia Pacific allergy 2023; (13(2)):60-65 doi:10.5415/apallergy.0000000000000100.

The multifactorial impact of receiving a hereditary angioedema diagnosis.

Raasch J, Glaum MC, O'Connor M

The World Allergy Organization journal 2023; (16(6)):100792 doi:10.1016/j.waojou.2023.100792.

Sensitivity to change and minimal clinically important difference of the angioedema control test.

Fijen LM, Vera C, Buttgereit T, et al.

Clinical and translational allergy 2023; (13(9)):e12295 doi:10.1002/clt2.12295.

A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.

Johnson F, Stenzl A, Hofauer B, et al.

Clinical reviews in allergy & immunology 2023; (65(3)):354-364 doi:10.1007/s12016-023-08972-2.

Pathogenic variant in SERPING1 gene causing autosomal dominant hereditary angioedema in early childhood.

Kron K, Joshi S

BMJ case reports 2023; (16(11)) doi:10.1136/bcr-2023-257212.

Screening for type II hereditary angioedema-the "poor man's c1-inhibitor function".

Jindal AK, Chiang V, Barman P, et al.

The journal of allergy and clinical immunology. Global 2024; (3(1)):100179 doi:10.1016/j.jacig.2023.100179.

[Hereditary angioedema due to C1-inhibitor deficiency, a national disease management programme].

Aberer W, Altrichter S, Cerpes U, et al.

Wiener klinische Wochenschrift 2023; (135(Suppl 8)):785-798 doi:10.1007/s00508-023-02298-x.

Recessive SERPING1 Variant Leads to Kinin-Kallikrein System Control Failure in a Consanguineous Brazilian Family with Hereditary Angioedema.

Maia LSM, Burger B, Ghannam A, et al.

Journal of clinical medicine 2023; (12(23)) doi:10.3390/jcm12237299.

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation.

Clermont AC, Murugesan N, Edwards HJ, et al.

Frontiers in pharmacology 2023; (14()):1287487 doi:10.3389/fphar.2023.1287487.

Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases.

Hioki C, Oda Y, Moriwaki S, Fukunaga A

The Journal of dermatology 2024; (51(6)):873-877 doi:10.1111/1346-8138.17106.

Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.

Srinivasan C, Ritchie B, Adatia A

Frontiers in immunology 2024; (15()):1339421 doi:10.3389/fimmu.2024.1339421.

Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency.

Vincent D, Parsopoulou F, Martin L, et al.

The journal of allergy and clinical immunology. Global 2024; (3(2)):100223 doi:10.1016/j.jacig.2024.100223.

The effect of estrogen-containing birth control pills on the constituents of bradykinin expression in plasma.

Birmingham JM, Wisnivesky J, Busse PJ

The journal of allergy and clinical immunology. Global 2024; (3(2)):100226 doi:10.1016/j.jacig.2024.100226.

Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.

Craig TJ, Levy DS, Reshef A, et al.

The Lancet. Haematology 2024; (11(6)):e436-e447 doi:10.1016/S2352-3026(24)00081-4.

Hereditary angioedema: current therapeutic management and future approaches.

Lamacchia D, Nappi E, Marzio V, et al.

Current opinion in allergy and clinical immunology 2024; (24(4)):257-265 doi:10.1097/ACI.0000000000000992.

Hereditary angioedema with normal C1 esterase inhibitor: Current paradigms and clinical dilemmas.

Radojicic C, Anderson J

Allergy and asthma proceedings 2024; (45(3)):147-157 doi:10.2500/aap.2024.45.240010.

Hereditary angioedema classification: Expanding knowledge by genotyping and endotyping.

Giavina-Bianchi P, Vivolo Aun M, Giavina-Bianchi M, et al.

The World Allergy Organization journal 2024; (17(5)):100906 doi:10.1016/j.waojou.2024.100906.

Altered levels of phospholipases C, diacylglycerols, endocannabinoids, and N-acylethanolamines in patients with hereditary angioedema due to FXII mutation.

Ferrara AL, Palestra F, Piscitelli F, et al.

Allergy 2025; (80(1)):287-296 doi:10.1111/all.16197.

Current and Emerging Therapeutics in Hereditary Angioedema.

Do T, Riedl MA

Immunology and allergy clinics of North America 2024; (44(3)):561-576 doi:10.1016/j.iac.2024.03.009.

Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy.

Staikuniene-Kozonis J, Staikunaite J, Gasiuniene E, Sematonyte J

Frontiers in pediatrics 2024; (12()):1408110 doi:10.3389/fped.2024.1408110.

Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.

Craig T, Tachdjian R, Bernstein JA, et al.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2024; (133(6)):712-719.e1 doi:10.1016/j.anai.2024.08.001.

Initial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: A Clinical Observation Study on Six Patients.

Yao W, Diao R, Yang B, et al.

International archives of allergy and immunology 2025; (186(3)):221-231 doi:10.1159/000541242.

A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema.

Sexton D, Faucette R, Rivera-Hernandez M, et al.

Frontiers in allergy 2024; (5()):1436855 doi:10.3389/falgy.2024.1436855.

A mechanistic model of in vitro plasma activation to evaluate therapeutic kallikrein-kinin system inhibitors.

Rezvani-Sharif A, Lioe H, Dower SK, et al.

PLoS computational biology 2024; (20(11)):e1012552 doi:10.1371/journal.pcbi.1012552.

Hereditary angioedema (HAE) in children and adolescents: New treatment options.

Fasshauer M, Wedi B

Allergologie select 2024; (8()):336-345 doi:10.5414/ALX02532E.

Advocacy in Action: International Patient Group Improves Hereditary Angioedema Diagnosis and Care Across the Asia-Pacific.

Wong JCY, Tsui CCW, Lao KCW, et al.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2025; doi:10.1111/cea.14623.

Impact of Dental Procedures on Hereditary Angioedema Attacks: An Exploratory Observational Study.

Nadasan V, Kiss KO, Borka-Balás R, Bara NA

Oral health & preventive dentistry 2025; (23()):173-182 doi:10.3290/j.ohpd.c_1907.

Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks.

Li HH, Aygören-Pürsün E, Magerl M, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):10 doi:10.1186/s13223-025-00955-6.

Expert Consensus on the Diagnosis and Treatment of Hereditary Angioedema in China (2024 Edition).

Xu Y, Liu S, Wang X, et al.

International archives of allergy and immunology 2026; (187(1)):61-73 doi:10.1159/000545808.

Identification of an elusive SERPING1 deletion in a family with hereditary angioedema type I utilizing soft clipping.

Wetherby K, Chiao J, Faulkner E, et al.

Frontiers in allergy 2025; (6()):1565283 doi:10.3389/falgy.2025.1565283.

Angioedema without urticaria: Diagnosis and management.

Young MC, Banerji A

Allergy and asthma proceedings 2025; (46(3)):185-191 doi:10.2500/aap.2025.46.250013.

Hereditary angioedema diagnosis: Reflecting on the past, envisioning the future.

Grumach AS, Riedl MA, Cheng L, et al.

The World Allergy Organization journal 2025; (18(6)):101060 doi:10.1016/j.waojou.2025.101060.

A Two-Decade-Delayed Diagnosis of Hereditary Angioedema: A Case Report.

Shrestha S, Yadav AK, Khadka D, et al.

Cureus 2025; (17(5)):e85019 doi:10.7759/cureus.85019.

Treatment Patterns and Characteristics of Patients with Hereditary Angioedema Treated with Lanadelumab: A US Retrospective Chart Review.

Watt M, Chang R, Yu LH, et al.

Drugs - real world outcomes 2025; (12(3)):351-365 doi:10.1007/s40801-025-00505-x.

Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis.

Riedl MA, Bernstein JA, Jacobs JS, et al.

The journal of allergy and clinical immunology. In practice 2025; (13(9)):2381-2389.e3 doi:10.1016/j.jaip.2025.06.018.

Impact of providing education on the recognition and differential diagnosis of angioedema among emergency department physicians.

Unal D, Demir S, Işik SR, et al.

The World Allergy Organization journal 2025; (18(8)):101101 doi:10.1016/j.waojou.2025.101101.

Expanding the Genetic and Clinical Spectrum of Hereditary Angioedema with Normal C1 Inhibitor: Novel Variants and Treatment Insights.

Gao H, Zhao Y, Chen S, et al.

Journal of clinical immunology 2025; (45(1)):124.

Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.

Farkas H, Anderson J, Bouillet L, et al.

The journal of allergy and clinical immunology. In practice 2025; (13(11)):3094-3103.e5 doi:10.1016/j.jaip.2025.08.020.

Quality of life and burden of disease in patients with hereditary angioedema and their caregivers.

Levy DS, Nagase FI, Cheung A, et al.

Allergy and asthma proceedings 2025; (46(5)):398-405 doi:10.2500/aap.2025.46.250048.

Sebetralstat: First Approval.

Blair HA

Drugs 2025; (85(11)):1499-1505 doi:10.1007/s40265-025-02239-0.

Real-World Evidence on the Management of Hereditary Angioedema With Normal C1 Inhibitor.

Lobão NTM, Bardou MLD, Vila SYC, et al.

The journal of allergy and clinical immunology. In practice 2026; (14(1)):233-242.e2 doi:10.1016/j.jaip.2025.10.001.

Misdiagnosed Hereditary Angioedema with Recurrent Abdominal Pain: A Novel SERPING1 Frameshift Variant.

Xie R, Wen R, Li Y, et al.

Journal of asthma and allergy 2025; (18()):1367-1375 doi:10.2147/JAA.S536943.

Donidalorsen: First Approval.

Syed YY

Drugs 2026; (86(2)):243-248 doi:10.1007/s40265-025-02257-y.

Hereditary Angioedema Prophylaxis Therapy: Berotralstat and Lanadelumab Safety Profile.

Donadoni M, La Cava L, Bizzi E, et al.

Medicina (Kaunas, Lithuania) 2025; (61(11)) doi:10.3390/medicina61111897.

Management of hereditary angioedema with normal C1Inh: a series of 163 French patients.

Bocquet A, Bouillet L, Hardy G, et al.

Orphanet journal of rare diseases 2025; (21(1)):5 doi:10.1186/s13023-025-04155-8.

Urgent diagnosis of hereditary angioedema in the ICU and ED: the critical role of rapid complement testing - a case report.

Dungan LS, Khalib K, Curley D, Keogan M

International journal of emergency medicine 2025; (18(1)):254 doi:10.1186/s12245-025-01057-1.

Treatment of Hereditary Angioedema With Plasma-Derived C1 Inhibitor: A Review.

Martinez-Saguer I, Pragst I, Worrall B, Bork K

Clinical and translational allergy 2025; (15(12)):e70126 doi:10.1002/clt2.70126.

Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema.

Yarlas A, Feld AJ, Bjorner JB, et al.

Clinical and translational allergy 2026; (16(1)):e70143 doi:10.1002/clt2.70143.

Patient Preferences for Long-Term Prophylactic Treatment in Hereditary Angioedema: A Discrete-Choice Experiment.

Villa KF, Mansfield C, Yarlas A, et al.

The patient 2026; (19(3)):481-495 doi:10.1007/s40271-025-00798-8.

Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world.

Davis-Lorton M, Tachdjian R, Lopez-Gonzalez L, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2026; (22(1)).

The International/Canadian hereditary angioedema guideline.

Betschel S, Binkley K, Borici-Mazi R, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2026; (22(1)).

A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.

Cancian M, Caballero T, Boccon-Gibod I, et al.

Frontiers in immunology 2026; (17()):1773279 doi:10.3389/fimmu.2026.1773279.

Monoclonal antibodies in the management of hereditary angioedema.

Farkas H, Voloncs-Mindszenthy L, Horváth HR

Expert opinion on biological therapy 2026; (26(5)):487-501 doi:10.1080/14712598.2026.2664733.

Garadacimab for the long-term prophylaxis of hereditary angioedema.

Aygören-Pürsün E, Treudler R, Staubach P, et al.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2026; doi:10.1111/ddg.70276.

Comprehensive care for hereditary angioedema: lessons learned from HAEmophilia Treatment Centers.

Uminski K, Goodyear D

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2026; (22(1)).